Join the Crohn's Disease group to help and get support from people like you.
Crohn's Disease News
Related terms: Crohns
Spatiotemporal Mapping IDs Four Stages of Inflammatory Bowel Disease Evolution
TUESDAY, May 6, 2025 – Machine learning has enabled spatiotemporal mapping of the four stages of the evolution of inflammatory bowel disease (IBD), according to a study published online April 30...
Monthly News Roundup - March 2025
FDA Approves Tremfya for Adults Patients with Active Crohn’s Disease In March, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (guselkumab) for the t...
FDA Approves Tremfya for Active Crohn Disease in Adults
MONDAY, March 24, 2025 – The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth...
Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD
MONDAY, March 24, 2025 – Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting premature death,...
FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease
HORSHAM, Pa. (March 20, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), the first and only IL-23 inhibitor o...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 – For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis, corticosteroid usage,...
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
WEDNESDAY, Feb 5, 2025 – Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study published in the March issue of...
Metrics From Wearable Devices Can Predict IBD Flares
FRIDAY, Jan. 24, 2025 – Physiological metrics from wearable devices can help identify inflammatory bowel disease (IBD) flares, according to a study published online Jan. 16 in Gastroenterology....
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
THURSDAY, Jan. 16, 2025 – The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, according to a press...
FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment...
Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease
FRIDAY, Jan. 3, 2025 – For pediatric patients with Crohn disease, early anti-tumor necrosis factor-alpha (anti-TNFα) therapy is beneficial in preventing the development of perianal fistula ...
Intestinal Ultrasound Feasible for Detecting Pediatric Inflammatory Bowel Disease
FRIDAY, Jan. 3, 2025 – Intestinal ultrasound (IU) can be considered a screening tool for pediatric inflammatory bowel disease (IBD), according to a study published online Dec. 24 in the Journal of ...
Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease
FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...
FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...
Inflammatory Bowel Disease on the Rise Globally in the Elderly
WEDNESDAY, Dec. 4, 2024 -- Inflammatory bowel disease (IBD) in older adults has become a global public health burden, according to a study published in the Jan. 31, 2025, issue of Autoimmunity R...
Further information
Related condition support groups
Crohn's Disease - Maintenance, Crohn's Disease - Acute, Inflammatory Bowel Disease
Related drug support groups
Humira, Stelara, Entyvio, Remicade, Skyrizi, cholestyramine, adalimumab, budesonide, ustekinumab, Cimzia